THOMAS SCIASCIA - 14 Aug 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Scientific Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
14 Aug 2024
Net transactions value
-$42,176
Form type
4
Filing time
16 Aug 2024, 16:47:10 UTC
Previous filing
31 May 2024
Next filing
21 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $143 +100 +0.05% $1.43 220,415 14 Aug 2024 Direct F1
transaction TRVI Common Stock Sale $275 -100 -0.05% $2.75 220,315 14 Aug 2024 Direct
transaction TRVI Common Stock Options Exercise $18,225 +12,745 +5.8% $1.43 233,060 15 Aug 2024 Direct
transaction TRVI Common Stock Sale $35,513 -12,745 -5.5% $2.79 220,315 15 Aug 2024 Direct F2
transaction TRVI Common Stock Options Exercise $26,684 +18,660 +8.5% $1.43 238,975 16 Aug 2024 Direct
transaction TRVI Common Stock Sale $51,440 -18,660 -7.8% $2.76 220,315 16 Aug 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -100 -0.21% $0.000000 47,901 14 Aug 2024 Common Stock 100 $1.43 Direct F4
transaction TRVI Stock Option (right to buy) Options Exercise $0 -12,745 -27% $0.000000 35,156 15 Aug 2024 Common Stock 12,745 $1.43 Direct F4
transaction TRVI Stock Option (right to buy) Options Exercise $0 -18,660 -53% $0.000000 16,496 16 Aug 2024 Common Stock 18,660 $1.43 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,882 shares purchased through the Issuer's employee stock purchase plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.8020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.